Recent guidelines strongly support the use of SGLT2-inhibitors after multiple studies have shown benefit in glycemic control along with reduction in CVD risk and CKD progression.24 These medications remain underutilized—as low as 32% in eligible patients with CKD and type 2 diabetics—largely due to cost and patient or physician preference.39 A collaborative approach among primary care providers, nephrologists, endocrinologists, and cardiologists should be pursued to enhance use. The gene discussed is SLC5A2; the disease is chronic kidney disease.